Drug Trial Radar · NCT00370032
Study to Assess the Effect Of Alosetron On Mucosal Blood Flow
Last checked: Nov 19, 2026Latest source record: May 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Dec 2006
Primary completion
Dec 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 30, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will look at colonic mucosal blood flow in subjects who have taken alosetron vs placebo and healthy volunteers vs diarrhea-predominant Irritable Bowel Syndrome (d-IBS) patients.
Conditions
- Irritable Colon
Interventions
alosetronDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Left Colon Mucosal Blood Flow (MBF)Time frame: Day 6 after each treatment period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.